respiratory failure

Tocilizumab (Anti-Human IL6R) is a neutralizing antibody against human interleukin-6 receptor (IL-6R) that blocks the binding of IL-6 to IL-6R, thereby inhibiting both classical and trans signaling. It can be used to study rheumatoid arthritis and has been suggested as a possible drug for the treatment of severe COVID-19.

Aviptadil Acetate (Vasoactive Intestinal Peptide acetate salt) induces pulmonary vasodilation and inhibits the proliferation of vascular SMCs and platelet aggregation. Avitadil acetate can be used for research on pulmonary fibrosis, pulmonary hypertension (PAH), and respiratory failure caused by SARS-CoV-2.

Doxapram (Dopram) is a respiratory stimulant that inhibits TASK-1, TASK-3, and TASK-1/TASK-3 heterodimer channels and is used to study ventilatory failure caused by apnea of ​​prematurity and exacerbation of chronic obstructive pulmonary disease.

Amiphenazole is a respiratory stimulant traditionally used as an antidote for barbiturate or opiate overdose, usually in combination with bemegride, as well as poisoning from other sedative drugs and treatment of respiratory failure from other causes.

GSK3527497 is a potent and selective inhibitor of Transient Receptor Potential Vanilloid‑4 (TRPV4) with IC50 = 12 nM) for the treatment of heart failure and respiratory diseases. GSK3527497 is a preclinical candidate suitable for oral and iv administration that is projected to inhibit TRPV4 effectively in patients from a low daily clinical dose.

GSK3491943 is a potent TRPV4 inhibitor with IC50 = 3.2 nM. GSK3491943 is a potential agent for the treatment of heart failure and respiratory diseases.

Mavrilimumab (CAM 3001) is a monoclonal antibody with antiviral activity that targets the α subunit of the granulocytic-macrophage colony-stimulating factor (GM-CSF) receptor, inhibiting downstream intracellular GM-CSF signaling. GM-CSF may contribute to an overactive inflammatory response linked to respiratory failure and death and could be used to study rheumatoid arthritis.